Reports Q2 revenue $38.1M vs. $16.5M last year.”We’re extremely pleased with our second quarter performance, which demonstrated solid revenue growth. Our Greenbrook integration continues to progress well, with record clinic revenue. We also reduced cash used in operations to just $3.5 million, better than our target,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics (STIM) “Our strong quarterly results are expected to help us achieve positive cash flow from operations in 2025 and I’m confident we’re well-positioned to continue executing on our strategic priorities and drive sustainable growth for the remainder of 2025. We’re also excited to welcome our new Chief Financial Officer, Steve Pfanstiel, who brings over two decades of experience driving growth and profitability at healthcare companies to the team.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Neuronetics Reports Q2 2025 Financial Results Surge
- Neuronetics announces new publication in JAACAP on depressed adolescents
- Neuronetics Appoints New CFO Amid Strategic Expansion
- Neuronetics CFO Furlong to retire, appoints Pfanstiel as new CFO
- Neuronetics announces presence at CTMSS meeting, progress in Greenbrook program